Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Rating) insider George Adi Mor sold 324,775 shares of Chemomab Therapeutics stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $2.08, for a total value of $675,532.00. Following the transaction, the insider now owns 324,775 shares in the company, valued at approximately $675,532. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Chemomab Therapeutics Price Performance
NASDAQ:CMMB opened at $2.09 on Friday. The stock has a market cap of $23.89 million, a PE ratio of -0.99 and a beta of 0.65. Chemomab Therapeutics Ltd. has a fifty-two week low of $1.75 and a fifty-two week high of $9.96. The stock’s 50-day moving average is $2.31 and its two-hundred day moving average is $2.97.
Hedge Funds Weigh In On Chemomab Therapeutics
A number of large investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. acquired a new position in shares of Chemomab Therapeutics in the 1st quarter valued at about $52,000. Citadel Advisors LLC acquired a new position in shares of Chemomab Therapeutics in the 3rd quarter valued at about $53,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Chemomab Therapeutics in the 1st quarter valued at about $134,000. Institutional investors and hedge funds own 28.87% of the company’s stock.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Get a free copy of the StockNews.com research report on Chemomab Therapeutics (CMMB)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.